OncoMatch/Clinical Trials/NCT06295926
Serplulimab Combined With CCRT for LS-SCLC.
Is NCT06295926 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Serplulimab for small cell lung cancer.
Treatment: Serplulimab — Small cell lung cancer(SCLC) has a poor prognosis and a relatively short overall survival time, urgently requiring innovative treatment strategies to improve the prognosis of such patients. Immunotherapy has become an important component of first-line therapy for extensive-stage small cell lung cancer (ES-SCLC). Studies have found that, compared to chemotherapy alone, the combination of Surlidumab with carboplatin and etoposide can extend the median overall survival in ES-SCLC to over 15 months. However, to date, research on the use of immunotherapy in combination with concurrent chemoradiotherapy (CCRT) in limited-stage small cell lung cancer (LS-SCLC) remains limited. This study aims to explore the clinical benefits of Surlidumab in combination with concurrent chemoradiotherapy in LS-SCLC and evaluate the safety of immunotherapy in combination with CCRT as first-line treatment for LS-SCLC. At the same time, it seeks to identify tumor-related biomarkers that can effectively predict the efficacy of immunotherapy and prognosis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage II, III (8th edition of AJCC Cancer Staging)
Excluded: Stage I
staged as limited stage (stage II-III according to the 8th edition of AJCC Cancer Staging)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: targeted therapy
not having received any prior targeted therapy
Cannot have received: chemotherapy
not having received any prior...chemotherapy
Cannot have received: radiation therapy
not having received any prior...radiation therapy
Cannot have received: immunotherapy
not having received any prior...immunotherapy
Cannot have received: surgery
Cancer patients who have undergone surgery...for small cell lung cancer
Lab requirements
Blood counts
sufficient bone marrow function (hematologic tests)
Kidney function
sufficient organ function (blood biochemistry, urine biochemistry)
Liver function
sufficient organ function (blood biochemistry)
Baseline hematologic, blood biochemistry, and urine biochemistry tests confirming sufficient bone marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify